TY - JOUR
T1 - On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology
AU - Chou, David B.
AU - Frismantas, Viktoras
AU - Milton, Yuka
AU - David, Rhiannon
AU - Pop-Damkov, Petar
AU - Ferguson, Douglas
AU - MacDonald, Alexander
AU - Vargel Bölükbaşı, Özge
AU - Joyce, Cailin E.
AU - Moreira Teixeira, Liliana S.
AU - Rech, Arianna
AU - Jiang, Amanda
AU - Calamari, Elizabeth
AU - Jalili-Firoozinezhad, Sasan
AU - Furlong, Brooke A.
AU - O’Sullivan, Lucy R.
AU - Ng, Carlos F.
AU - Choe, Youngjae
AU - Marquez, Susan
AU - Myers, Kasiani C.
AU - Weinberg, Olga K.
AU - Hasserjian, Robert P.
AU - Novak, Richard
AU - Levy, Oren
AU - Prantil-Baun, Rachelle
AU - Novina, Carl D.
AU - Shimamura, Akiko
AU - Ewart, Lorna
AU - Ingber, Donald E.
N1 - Funding Information:
This research was sponsored by funding from: the US Food and Drug Administration (grants HHSF223201310079C and 75F40119C10098), the Defense Advanced Research Projects Agency (under Cooperative Agreement Number W911NF-12-2-0036), AstraZeneca and the Wyss Institute for Biologically Inspired Engineering (to D.E.I.); the US National Institutes of Health (R24 DK099808 and 5U01HL134812 to A.S., R01 DK102165 to C.D.N. and training grant 5T32CA009216-37 to D.B.C.); and the Department of Defense (W81XWH-14-1-0124 to C.D.N.). Additional funding was provided by the Dana-Farber Cancer Center Claudia Adams Barr Award (to C.E.J.) and the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine (to A.R.). The authors thank S. Sweeney for helpful discussions, P. Machado and J. Caramanica for machining expertise, and M. DeLelys, R. Matthews, J. Houston, J. Patel, D. Kingman, A. Shay, J. Graham, S. Chung, T. Spitzer and F. Preffer at the Massachusetts General Hospital, as well as M. Fleming and M. Armant at Boston Children’s Hospital for invaluable help in relation to working with patient data and samples.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - The inaccessibility of living bone marrow (BM) hampers the study of its pathophysiology under myelotoxic stress induced by drugs, radiation or genetic mutations. Here, we show that a vascularized human BM-on-a-chip (BM chip) supports the differentiation and maturation of multiple blood cell lineages over 4 weeks while improving CD34+ cell maintenance, and that it recapitulates aspects of BM injury, including myeloerythroid toxicity after clinically relevant exposures to chemotherapeutic drugs and ionizing radiation, as well as BM recovery after drug-induced myelosuppression. The chip comprises a fluidic channel filled with a fibrin gel in which CD34+ cells and BM-derived stromal cells are co-cultured, a parallel channel lined by human vascular endothelium and perfused with culture medium, and a porous membrane separating the two channels. We also show that BM chips containing cells from patients with the rare genetic disorder Shwachman–Diamond syndrome reproduced key haematopoietic defects and led to the discovery of a neutrophil maturation abnormality. As an in vitro model of haematopoietic dysfunction, the BM chip may serve as a human-specific alternative to animal testing for the study of BM pathophysiology.
AB - The inaccessibility of living bone marrow (BM) hampers the study of its pathophysiology under myelotoxic stress induced by drugs, radiation or genetic mutations. Here, we show that a vascularized human BM-on-a-chip (BM chip) supports the differentiation and maturation of multiple blood cell lineages over 4 weeks while improving CD34+ cell maintenance, and that it recapitulates aspects of BM injury, including myeloerythroid toxicity after clinically relevant exposures to chemotherapeutic drugs and ionizing radiation, as well as BM recovery after drug-induced myelosuppression. The chip comprises a fluidic channel filled with a fibrin gel in which CD34+ cells and BM-derived stromal cells are co-cultured, a parallel channel lined by human vascular endothelium and perfused with culture medium, and a porous membrane separating the two channels. We also show that BM chips containing cells from patients with the rare genetic disorder Shwachman–Diamond syndrome reproduced key haematopoietic defects and led to the discovery of a neutrophil maturation abnormality. As an in vitro model of haematopoietic dysfunction, the BM chip may serve as a human-specific alternative to animal testing for the study of BM pathophysiology.
UR - http://www.scopus.com/inward/record.url?scp=85078444118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078444118&partnerID=8YFLogxK
U2 - 10.1038/s41551-019-0495-z
DO - 10.1038/s41551-019-0495-z
M3 - Article
C2 - 31988457
AN - SCOPUS:85078444118
SN - 2157-846X
VL - 4
SP - 394
EP - 406
JO - Nature Biomedical Engineering
JF - Nature Biomedical Engineering
IS - 4
ER -